LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 52

Search options

  1. Article ; Online: Characteristics of Neuroimaging and Behavioural Phenotype in Polish Patients with PIGV-CDG—An Observational Study and Literature Review

    Hutny, Michal / Lipinski, Patryk / Jezela-Stanek, Aleksandra

    Genes (Basel). 2023 May 31, v. 14, no. 6

    2023  

    Abstract: Congenital disorders of glycosylation (CDGs) are a wide group of genetic diseases characterised by a severe clinical spectrum, consisting of developmental delays, dysmorphisms, and neurological deficits. Mutations in the PIGV gene lead to a disorder ... ...

    Abstract Congenital disorders of glycosylation (CDGs) are a wide group of genetic diseases characterised by a severe clinical spectrum, consisting of developmental delays, dysmorphisms, and neurological deficits. Mutations in the PIGV gene lead to a disorder called hyperphosphatasia with impaired intellectual development syndrome 1 (HPMRS1), distinct from other CDGs in terms of hyperphosphatemia related to abnormal ALP activity and brachytelephalangy. This article discusses the phenotype of six Polish patients with HPMRS1 with a special focus on behavioural and imaging features, which were not addressed in 26 previously reported cases. The medical records of six patients aged 6 to 22 years were collected and analysed. In all cases, the same PIGV homozygotic mutation (c.1022C>A; p.Ala341Glu) was found, although the patients presented a diverse spectrum of neurological and developmental disorders, concerning in most cases the muscular tonus and general developmental delay. The most prevalent dysmorphic features included hypertelorism, high palate, and finger anomalies, whereas other characteristics present in all previously described cases, such as a short, broad nose and brachytelephalangy, were less frequently observed. Similarly to previous reports, the magnetic resonance (MR) and computed tomography (CT) head scans returned varied results, including physiological and pathological brain images in equal measure, the latter of which consisted of cortical atrophy, delayed myelination, hydrocephalus, and hypoplastic corpus callosum. Each patient exhibited symptoms characteristic of autism spectrum disorders, especially in terms of attention deficits, as well as controlling and expressing emotions. The most common type of sensory processing disorder was over-responsivity. Despite the low prevalence of HPMRS1, the patients reported in the literature presented a rather uniform phenotype, which does not correspond with the one found in each individual of the studied group. Behavioural disorders and sensory impairment require additional care and awareness considering the global developmental delay often observed in these patients.
    Keywords atrophy ; autism ; brain ; computed tomography ; genes ; glycosylation ; head ; hydrocephalus ; magnetism ; mutation ; myelination ; nose ; observational studies ; palate ; patients ; phenotype
    Language English
    Dates of publication 2023-0531
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article ; Online
    ZDB-ID 2527218-4
    ISSN 2073-4425
    ISSN 2073-4425
    DOI 10.3390/genes14061208
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Characteristics of Neuroimaging and Behavioural Phenotype in Polish Patients with PIGV-CDG-An Observational Study and Literature Review.

    Hutny, Michal / Lipinski, Patryk / Jezela-Stanek, Aleksandra

    Genes

    2023  Volume 14, Issue 6

    Abstract: Congenital disorders of glycosylation (CDGs) are a wide group of genetic diseases characterised by a severe clinical spectrum, consisting of developmental delays, dysmorphisms, and neurological deficits. Mutations in ... ...

    Abstract Congenital disorders of glycosylation (CDGs) are a wide group of genetic diseases characterised by a severe clinical spectrum, consisting of developmental delays, dysmorphisms, and neurological deficits. Mutations in the
    MeSH term(s) Humans ; Poland ; Abnormalities, Multiple/diagnostic imaging ; Abnormalities, Multiple/genetics ; Phenotype ; Neuroimaging ; Observational Studies as Topic
    Language English
    Publishing date 2023-05-31
    Publishing country Switzerland
    Document type Review ; Journal Article
    ZDB-ID 2527218-4
    ISSN 2073-4425 ; 2073-4425
    ISSN (online) 2073-4425
    ISSN 2073-4425
    DOI 10.3390/genes14061208
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Congenital Disorders of Glycosylation: What Clinicians Need to Know?

    Lipiński, Patryk / Tylki-Szymańska, Anna

    Frontiers in pediatrics

    2021  Volume 9, Page(s) 715151

    Abstract: Congenital disorders of glycosylation (CDG) are a group of clinically heterogeneous disorders characterized by defects in the synthesis of glycans and their attachment to proteins and lipids. This manuscript aims to provide a classification of the ... ...

    Abstract Congenital disorders of glycosylation (CDG) are a group of clinically heterogeneous disorders characterized by defects in the synthesis of glycans and their attachment to proteins and lipids. This manuscript aims to provide a classification of the clinical presentation, diagnostic methods, and treatment of CDG based on the literature review and our own experience (referral center in Poland). A diagnostic algorithm for CDG was also proposed. Isoelectric focusing (IEF) of serum transferrin (Tf) is still the method of choice for diagnosing N-glycosylation disorders associated with sialic acid deficiency. Nowadays, high-performance liquid chromatography, capillary zone electrophoresis, and mass spectrometry techniques are used, although they are not routinely available. Since next-generation sequencing became more widely available, an improvement in diagnostics has been observed, with more patients and novel CDG subtypes being reported. Early and accurate diagnosis of CDG is crucial for timely implementation of appropriate therapies and improving clinical outcomes. However, causative treatment is available only for few CDG types.
    Language English
    Publishing date 2021-09-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2021.715151
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Disturbance of lipid homeostasis in lysosomal lipase deficiency – pathomechanism, diagnosis and treatment

    Lipiński, Patryk / Tylki-Szymańska, Anna

    Postepy biochemii

    2021  Volume 67, Issue 3, Page(s) 231–235

    Abstract: Lysosomal acid lipase (LAL) plays a key role in lipid metabolism through the hydrolysis of cholesteryl esters and triglycerides in lysosomes. LAL deficiency is a rare autosomal recessive lysosomal storage disease caused by deleterious mutations in the ... ...

    Title translation Zaburzenie homeostazy lipidowej w deficycie lizosomalnej lipazy – patomechanizm, diagnostyka i leczenie.
    Abstract Lysosomal acid lipase (LAL) plays a key role in lipid metabolism through the hydrolysis of cholesteryl esters and triglycerides in lysosomes. LAL deficiency is a rare autosomal recessive lysosomal storage disease caused by deleterious mutations in the LIPA gene. In the case of LAL deficiency, cholesteryl esters and triglycerides accumulate within the lysosomes. The up-regulation of endogenous cholesterol production, increased synthesis of apolipoprotein B (ApoB) and increased production of very-low-density lipoprotein cholesterol (VLDL-C) is observed. The diagnosis is easy due to the currently available method of testing the enzyme activity in a dry blood spot. Molecular analysis is necessary to verify the clinical and biochemical diagnosis and to analyze the genotype-phenotype correlation. Sebelipase alfa is a recombinant human lysosomal lipase intended for use in enzyme replacement therapy in patients with LAL deficiency.
    MeSH term(s) Homeostasis ; Humans ; Lipase ; Lipids ; Lysosomes ; Wolman Disease/diagnosis ; Wolman Disease/genetics ; Wolman Disease/therapy
    Chemical Substances Lipids ; Lipase (EC 3.1.1.3)
    Language Polish
    Publishing date 2021-07-19
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 414019-9
    ISSN 0032-5422
    ISSN 0032-5422
    DOI 10.18388/pb.2021_389
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Efficacy of Enzyme Replacement Therapy on the range of motion of the upper and lower extremities in 16 Polish patients with mucopolysaccharidosis type II: A long-term follow-up study.

    Marucha, Jolanta / Lipiński, Patryk / Tylki-Szymańska, Anna

    Acta biochimica Polonica

    2022  Volume 69, Issue 1, Page(s) 251–255

    Abstract: Background: Enzyme replacement therapy (ERT) with idursulfase is available for patients with mucopolysaccharidosis (MPS) type II, and improvements in certain somatic signs and symptoms have been reported. The aim of the study was to assess the ... ...

    Abstract Background: Enzyme replacement therapy (ERT) with idursulfase is available for patients with mucopolysaccharidosis (MPS) type II, and improvements in certain somatic signs and symptoms have been reported. The aim of the study was to assess the effectiveness of ERT with idursulfase (Elaprase®) on the passive joint range of motion (JROM) in the upper and lower extremities of patients with MPS II.
    Methods: The study included 16 Polish patients diagnosed with MPS II and followed in our Institute in the years 2009-2016. The study group was divided for groups of neuronopathic (group 1, n=12) and non-neuronopathic (group 2, n=4) patients. A passive JROM was measured with a goniometer by one physiotherapist, while in group 1 it was assessed at baseline and after both short-term (52 weeks) and long-term (mean 230 weeks, range: 108-332 weeks) ERT. In group 2, it was assessed at baseline and after short-term ERT (68-85 weeks, no data for long-term ERT).
    Results: In group 1, after 52 weeks of ERT, we observed some improvement of passive ROM in wrist flexion (5/12 patients), shoulder abduction and wrist extension (3/12 patients), shoulder flexion, elbow and knee extension (2/12 patients). After long-term ERT (mean 230 weeks), the improvement in JROM was observed only in 2 patients. There was no improvement in the shoulder abduction, elbow flexion and extension, hip and knee extension. In group 2, the improvement in passive ROM was observed in several joints: shoulder flexion, wrist flexion and extension improved (2/4 patients) and shoulder abduction (1/4 patients).
    Conclusion: ERT is of low efficacy on correcting the range of motion of joints in MPS II patients.
    MeSH term(s) Adult ; Child ; Child, Preschool ; Enzyme Replacement Therapy/methods ; Female ; Follow-Up Studies ; Humans ; Iduronate Sulfatase/therapeutic use ; Infant ; Joint Diseases/drug therapy ; Joint Diseases/physiopathology ; Lower Extremity/physiopathology ; Male ; Mucopolysaccharidosis II/drug therapy ; Mucopolysaccharidosis II/physiopathology ; Poland ; Range of Motion, Articular ; Upper Extremity/physiopathology
    Chemical Substances Iduronate Sulfatase (EC 3.1.6.13) ; idursulfase (EC 3.1.6.13)
    Language English
    Publishing date 2022-02-28
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 595762-x
    ISSN 1734-154X ; 0001-527X
    ISSN (online) 1734-154X
    ISSN 0001-527X
    DOI 10.18388/abp.2020_6071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Pharmacological chaperone therapy for the treatment of inborn errors of metabolism

    Lipiński, Patryk / Jezela-Stanek, Aleksandra / Tylki-Szymańska, Anna

    Postepy biochemii

    2022  Volume 68, Issue 3, Page(s) 255–263

    Abstract: The article describes the mechanism of molecular and pharmacological chaperones in the treatment of inborn errors of metabolism. The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher ... ...

    Title translation Stosowanie farmakologicznych chaperonów w leczeniu wrodzonych chorób metabolicznych.
    Abstract The article describes the mechanism of molecular and pharmacological chaperones in the treatment of inborn errors of metabolism. The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher disease and Parkinson’s disease associated with GBA variants has been reviewed.
    MeSH term(s) Humans ; Mutation ; Gaucher Disease/complications ; Gaucher Disease/drug therapy ; Ambroxol/pharmacology ; Ambroxol/therapeutic use ; Parkinson Disease/drug therapy
    Chemical Substances Ambroxol (200168S0CL)
    Language Polish
    Publishing date 2022-07-20
    Publishing country Poland
    Document type Review ; English Abstract ; Journal Article
    ZDB-ID 414019-9
    ISSN 0032-5422
    ISSN 0032-5422
    DOI 10.18388/pb.2021_451
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Congenital disorder of deglycosylation associated with N-glycanse 1 deficiency

    Lipiński, Patryk / Tylki-Szymańska, Anna

    Postepy biochemii

    2020  Volume 66, Issue 1, Page(s) 38–41

    Abstract: Together with the lysosomal storage diseases, N-glycanase 1 deficiency is a congenital disorder of deglycosylation, which has been diagnosed in 27 patients, including two of them from Poland. The pathogenesis remains unknown, however, the main role is ... ...

    Title translation Wrodzone zaburzenie deglikozylacji związane z deficytem N-glikanazy 1.
    Abstract Together with the lysosomal storage diseases, N-glycanase 1 deficiency is a congenital disorder of deglycosylation, which has been diagnosed in 27 patients, including two of them from Poland. The pathogenesis remains unknown, however, the main role is attributed to the disturbed endoplasmic reticulum-associated protein degradation process. The most characteristic symptoms include global developmental disability, hyperkinetic movement disorder, hypo-/alacrimia, and elevated serum transaminases. Identification of pathogenic variants in the NGLY1 gene is required to confirm the diagnosis.
    MeSH term(s) Congenital Disorders of Glycosylation/diagnosis ; Congenital Disorders of Glycosylation/genetics ; Glycosylation ; Humans ; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase/deficiency ; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase/genetics
    Chemical Substances Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase (EC 3.5.1.52)
    Language Polish
    Publishing date 2020-02-10
    Publishing country Poland
    Document type Journal Article ; Review
    ZDB-ID 414019-9
    ISSN 0032-5422
    ISSN 0032-5422
    DOI 10.18388/pb.2020_306
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: [Progressive familial intrahepatic cholestasis type 3].

    Lipiński, Patryk / Jankowska, Irena

    Developmental period medicine

    2019  Volume 22, Issue 4, Page(s) 385–389

    Abstract: Progressive familial intrahepatic cholestasis is caused by mutations in the ABCB4 gene and belongs to the family of familial intrahepatic cholestais disorders inherited in an autosomal recessive pattern. To date, about 200 patients with various ... ...

    Abstract Progressive familial intrahepatic cholestasis is caused by mutations in the ABCB4 gene and belongs to the family of familial intrahepatic cholestais disorders inherited in an autosomal recessive pattern. To date, about 200 patients with various hepatobiliary disorders associated with ABCB4 gene mutations have been described in the literature. The aim of this manuscript was to describe the pathogenesis, clinical presentation, diagnostic process and treatment of progressive familial intrahepatic cholestais type 3, based on the literature review.
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily B/genetics ; Cholestasis, Intrahepatic/diagnosis ; Cholestasis, Intrahepatic/genetics ; Cholestasis, Intrahepatic/physiopathology ; Cholestasis, Intrahepatic/therapy ; Genetic Predisposition to Disease ; Humans ; Mutation
    Chemical Substances ATP Binding Cassette Transporter, Subfamily B ; multidrug resistance protein 3 (9EI49ZU76O)
    Language Polish
    Publishing date 2019-01-08
    Publishing country Poland
    Document type Journal Article ; Review
    ZDB-ID 2576573-5
    ISSN 1428-345X
    ISSN 1428-345X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Congenital disorders of glycosylation: Prevalence, incidence and mutational spectrum in the Polish population.

    Lipiński, Patryk / Bogdańska, Anna / Tylki-Szymańska, Anna

    Molecular genetics and metabolism reports

    2021  Volume 27, Page(s) 100726

    Abstract: Introduction: The incidence and prevalence of congenital disorders of glycosylation (CDG) have not been well established. The aim of the study was to evaluate the prevalence, incidence and genotypes of CDG patients diagnosed during the last 23 years in ... ...

    Abstract Introduction: The incidence and prevalence of congenital disorders of glycosylation (CDG) have not been well established. The aim of the study was to evaluate the prevalence, incidence and genotypes of CDG patients diagnosed during the last 23 years in Poland (1997 - 30th October 2020).
    Material and methods: The diagnosis was based on serum Tf IEF which is performed at The Children's Memorial Health Institute (CMHI) in Warsaw. Based on demographic data, the prevalence of CDG among the Polish population in 2020 as well as the birth prevalence of CDG from 1990 to 2020 were estimated.
    Results: 39 patients (from 35 families) with molecularly confirmed CDG were diagnosed, including 17 (44%) patients (from 16 families) with PMM2-CDG. The c.422G > A, p.Arg141His and c.691G > A, p.Val231Met pathogenic missense variants were the most common identified PMM2 variants. Eleven other patients were diagnosed with CDG based on serum Tf IEF analysis only; the molecular analysis is pending. Ten CDG patients died, including 6 with PMM2-CDG, 1 with PGM1-CDG and 1 with DPAGT1-CDG. The prevalence of CDG in the Polish population was estimated at approximately 1 per million while that of PMM2 at 0.4 per million. The annual incidence of CDG was estimated at 0.013 per 100,000 people in 2020.
    Conclusions: A low frequence of CDG in our study could be underestimated.
    Language English
    Publishing date 2021-02-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2821908-9
    ISSN 2214-4269
    ISSN 2214-4269
    DOI 10.1016/j.ymgmr.2021.100726
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach.

    Szymańska-Rożek, Paulina / Czartoryska, Barbara / Kleinotiene, Grazina / Lipiński, Patryk / Tylki-Szymańska, Anna / Ługowska, Agnieszka

    Biomolecules

    2023  Volume 13, Issue 3

    Abstract: Chitotriosidase is an enzyme produced and secreted in large amounts by activated macrophages, especially macrophages loaded with phagocytozed glycosphingolipid in Gaucher disease. Macrophages phagocytose decayed blood cells that contain a lot of ... ...

    Abstract Chitotriosidase is an enzyme produced and secreted in large amounts by activated macrophages, especially macrophages loaded with phagocytozed glycosphingolipid in Gaucher disease. Macrophages phagocytose decayed blood cells that contain a lot of sphingolipid-rich cell membranes. In Gaucher disease, due to a deficit in beta-glucocerebrosidase activity, the phagocytozed substrate glucocerebroside cannot undergo further catabolism. In such a situation, macrophages secrete chitotriosidase in proportion to the degree of overload. Gaucher disease (GD) is a recessively inherited disorder resulting in storage of glucosylceramide (GlcCer) in lysosomes of tissue macrophages. It is directly caused by the deficiency of beta-glucocerebrosidase (GBA) activity. Chitotriosidase has been measured systematically each year in the same group of 49 patients with type 1 and 3 GD for over 20 years. Our analysis showed that chitotriosidase is very sensitive biomarker to enzyme replacement therapy (ERT). The response to treatment introduction is of an almost immediate nature, lowering pathologically high chitotriosidase levels by a factor of 2 in a time scale of 8 months, on average. Long term enzyme replacement therapy (ERT) brings chitotriosidase activity close to reference values. Finally, reducing the dose of ERT quickly boosts chitotriosidase activity, but restoring the initial dose of treatment brings chitotriosidase level of activity back onto the decreasing time trajectory.
    MeSH term(s) Humans ; Gaucher Disease/drug therapy ; Gaucher Disease/metabolism ; Glucosylceramidase ; Longitudinal Studies ; Hexosaminidases/metabolism ; Hexosaminidases/therapeutic use ; Glucosylceramides/metabolism ; Glucosylceramides/therapeutic use
    Chemical Substances Glucosylceramidase (EC 3.2.1.45) ; chitotriosidase (EC 3.2.1.-) ; Hexosaminidases (EC 3.2.1.-) ; Glucosylceramides
    Language English
    Publishing date 2023-02-24
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom13030436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top